文献速递临床试验与 GCP

持续性心房颤动患者肺静脉隔离联合与不联合后壁隔离对房性心律失常复发的影响:CAPLA随机临床试验

Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

CAPLA多中心随机试验将338例首次接受导管消融的症状性持续性心房颤动患者按1:1分为肺静脉隔离联合后壁隔离组(n=170)与单纯肺静脉隔离组(n=168),随访12个月。单次手术后停用抗心律失常药物时,两组无房性心律失常复发率分别为52.4%与53.6%(组间差异-1.2%;HR 0.99,95%CI 0.73-1.36;P=0.98)。作者认为,这些发现不支持在持续性心房颤动消融中经验性加做后壁隔离。

要点

  • 加做后壁隔离未改善12个月无房性心律失常生存(52.4% vs 53.6%;P=0.98)。
  • 联合后壁隔离组手术时间与消融时间均显著长于单纯肺静脉隔离组。
  • 作者认为这些发现不支持经验性加做后壁隔离。

核心结论

  • 在接受首次导管消融的持续性心房颤动患者中,肺静脉隔离加后壁隔离与单纯肺静脉隔离相比,未显著改善12个月无房性心律失常生存。
  • 作者认为,这些发现不支持在持续性心房颤动消融中经验性加做后壁隔离。

研究设计与样本

  • 由研究者发起的多中心随机临床试验,涉及3个国家(澳大利亚、加拿大、英国)的11个中心。
  • 有症状的持续性心房颤动患者按1:1随机分为肺静脉隔离联合后壁隔离组(n=170)或单纯肺静脉隔离组(n=168)。
  • 患者入组时间为2018年7月至2021年3月,1年随访于2022年3月完成。
  • 共338例患者被随机(中位年龄65.6岁[IQR 13.1];76.9%为男性),330例(97.6%)完成研究。
  • 联合后壁隔离组行wide antral pulmonary vein isolation后,加做顶部与底部线性消融以实现后壁电隔离;单纯肺静脉隔离组仅行wide antral pulmonary vein isolation。

主要发现

  • 12个月后,联合后壁隔离组89例(52.4%)在单次手术后未用抗心律失常药物情况下无房性心律失常复发,单纯肺静脉隔离组90例(53.6%)(组间差异-1.2%;HR 0.99,95%CI 0.73-1.36;P=0.98)。
  • 多次手术后用或不用抗心律失常药物无房性心律失常:联合后壁隔离组58.2% vs 单纯肺静脉隔离组60.1%(HR 1.10,95%CI 0.79-1.55;P=0.57)。
  • 多次手术后用或不用抗心律失常药物无有症状心房颤动:联合后壁隔离组68.2% vs 单纯肺静脉隔离组72%(HR 1.20,95%CI 0.80-1.78;P=0.36)。
  • 12个月心房颤动负荷:联合后壁隔离组0%(IQR 0%-2.3%)vs 单纯肺静脉隔离组0%(IQR 0%-2.8%),P=0.47。
  • 平均手术时间联合后壁隔离组142分钟(SD 69)vs 单纯肺静脉隔离组121分钟(SD 57),P<0.001;平均消融时间联合后壁隔离组34分钟(SD 21)vs 单纯肺静脉隔离组28分钟(SD 12),P<0.001;联合后壁隔离组并发症6例,单纯肺静脉隔离组4例。

关键数值与推荐

  • 主要终点为单次消融手术后12个月,未用抗心律失常药物且无任何记录到的持续超过30秒的房性心律失常。
  • 23项次要终点包括多次手术后用或不用抗心律失常药物的无房性心律失常生存、多次手术后用或不用抗心律失常药物的无有症状心房颤动生存、12个月时两组间心房颤动负荷、手术结局与并发症。
  • 次要终点中有9项显示无显著差异,包括多次手术后用或不用抗心律失常药物的无房性心律失常生存(P=0.57)、无有症状心房颤动生存(P=0.36)与心房颤动负荷(P=0.47)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pulmonary vein isolation (PVI) alone is less effective in patients with persistent atrial fibrillation (AF) compared with paroxysmal AF. The left atrial posterior wall may contribute to maintenance of persistent AF, and posterior wall isolation (PWI) is a common PVI adjunct. However, PWI has not been subjected to randomized comparison. OBJECTIVE: To compare PVI with PWI vs PVI alone in patients with persistent AF undergoing first-time catheter ablation. DESIGN, SETTING, AND PARTICIPANTS: Investigator initiated, multicenter, randomized clinical trial involving 11 centers in 3 countries (Australia, Canada, UK). Symptomatic patients with persistent AF were randomized 1:1 to either PVI with PWI or PVI alone. Patients were enrolled July 2018-March 2021, with 1-year follow-up completed March 2022. INTERVENTIONS: The PVI with PWI group (n = 170) underwent wide antral pulmonary vein isolation followed by posterior wall isolation involving linear ablation at the roof and floor to achieve electrical isolation. The PVI-alone group (n = 168) underwent wide antral pulmonary vein isolation alone. MAIN OUTCOMES AND MEASURES: Primary end point was freedom from any documented atrial arrhythmia of more than 30 seconds without antiarrhythmic medication at 12 months, after a single ablation procedure. The 23 secondary outcomes included freedom from atrial arrhythmia with/without antiarrhythmic medication after multiple procedures, freedom from symptomatic AF with/without antiarrhythmic medication after multiple procedures, AF burden between study groups at 12 months, procedural outcomes, and complications. RESULTS: Among 338 patients randomized (median age, 65.6 [IQR, 13.1] years; 76.9% men), 330 (97.6%) completed the study. After 12 months, 89 patients (52.4%) assigned to PVI with PWI were free from recurrent atrial arrhythmia without antiarrhythmic medication after a single procedure, compared with 90 (53.6%) assigned to PVI alone (between-group difference, -1.2%; hazard ratio [HR], 0.99 [95% CI, 0.73-1.36]; P = .98). Of the secondary end points, 9 showed no significant difference, including freedom from atrial arrhythmia with/without antiarrhythmic medication after multiple procedures (58.2% for PVI with PWI vs 60.1% for PVI alone; HR, 1.10 [95% CI, 0.79-1.55]; P = .57), freedom from symptomatic AF with/without antiarrhythmic medication after multiple procedures (68.2% vs 72%; HR, 1.20 [95% CI, 0.80-1.78]; P = .36) or AF burden (0% [IQR, 0%-2.3%] vs 0% [IQR, 0%-2.8%], P = .47). Mean procedural times (142 [SD, 69] vs 121 [SD, 57] minutes, P < .001) and ablation times (34 [SD, 21] vs 28 [SD, 12] minutes, P < .001) were significantly shorter for PVI alone. There were 6 complications for PVI with PWI and 4 for PVI alone. CONCLUSIONS AND RELEVANCE: In patients undergoing first-time catheter ablation for persistent AF, the addition of PWI to PVI alone did not significantly improve freedom from atrial arrhythmia at 12 months compared with PVI alone. These findings do not support the empirical inclusion of PWI for ablation of persistent AF. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12616001436460.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kistler PM, Chieng D, Sugumar H, et al. Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial. JAMA. 2023. PMID: 36625809. doi:10.1001/jama.2022.23722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。